Commentary: Psychedelics and psychotherapy: Cognitive-behavioral approaches as default
John Burton, Austin Ratner, Timothy Cooper, Jeffrey Guss
Frontiers in Psychology September 30, 2022 DOI: 10.3389/fpsyg.2022.1020222 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Keywords | Psychoanalysis Cbt Psychodynamic psychotherapies Act Dbt |
| Key points | Argues that previous research on psilocybin for depression has methodological limitations, including inadequate blinding and expectancy effects, which may overstate its efficacy. Proposes that future studies should employ more rigorous designs, such as active placebos, to better evaluate the treatment. |
Abstract
GENERAL COMMENTARY article Front. Psychol., 30 September 2022Sec. Psychology for Clinical Settings Volume 13 - 2022 | https://doi.org/10.3389/fpsyg.2022.1020222
Citations in the library
Cited by 7
- Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases Cochrane Database of Systematic Reviews September 11, 2024
- Psychedelic Therapy as Form of Life Neuroethics March 16, 2024
- Trauma-Informed Care in Psychedelic Therapy Research: A Qualitative Literature Review of Evidence-Based Psychotherapy Interventions in PTSD and Psychedelic Therapy Across Conditions. Neuropsychiatric Disease and Treatment 2024
- Key competencies for psychedelic treatment in real-world mental health care settings. General Hospital Psychiatry 2025
- What is needed for the roll-out of psychedelic treatments? Current Opinion in Psychiatry July 1, 2024
and 2 more in the library